Patient preference for second- and third-line therapies in type 2 diabetes: a prespecified secondary endpoint of the TriMaster study. (2023)
Attributed to:
Developing a decision support tool to enable precision treatment of type 2 diabetes
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1038/s41591-022-02121-6
PubMed Identifier: 36477734
Publication URI: http://europepmc.org/abstract/MED/36477734
Type: Journal Article/Review
Volume: 29
Parent Publication: Nature medicine
Issue: 2
ISSN: 1078-8956